We will present financial results for the first quarter of 2025 on Tuesday, April 29, 2025 at 4:30 PM ET via live webcast and conference call. Learn more: https://t.co/20hae2UERy $SAGE
We support @MMHLA2’s first-ever National #DayofAction for #MaternalMentalHealth. About 1 in 8 women report experiencing symptoms of #postpartumdepression, yet many lack support. Together, we can help drive lasting change by raising awareness and advocating for better care.
We will present financial results for the fourth quarter and full year of 2024 on Tuesday, February 11, 2025 at 4:30 PM ET via live webcast and conference call. Learn more: https://t.co/brpPhp8FdD $SAGE
We look forward to our presentation at @jpmorgan Healthcare Conference on January 15 at 8:15 AM PST. Join the live webcast and hear about the year ahead: https://t.co/X3BtYMfn4w #JPM25
On December 4th, join us for our fireside chat at the 2024 @Piper_Sandler Healthcare Conference. The #LIVE webcast begins streaming at 9:00 AM ET. Watch here: https://t.co/QdHpzrtbm0 $SAGE
This week at @PsychCongress, Sage Therapeutics, in partnership with @NAMICommunicate and @Biogen, shared new insights into #postpartumdepression (PPD) and its impact on women and families.
We're proud to announce that our joint research poster focused on the burden of PPD has been selected as a #PsychCongress2024 poster award finalist, underscoring the importance of improving the standard of care for the #maternalmentalhealth community.
Discover more about maternal mental health and resources through NAMI: https://t.co/RBBraREJGf
The Sage team is excited to attend @PsychCongress this week. We look forward to connecting with industry leaders dedicated to improving the diagnosis and treatment of maternal mental health and postpartum depression (PPD).
Learn more here: https://t.co/KeEhI2mV49 #PsychCongress2024
Update: We will present third quarter financial results on October 29th, 2024 at 4:30 pm ET via live webcast and conference call. Learn more: https://t.co/CEUdbAQwev $SAGE
Today, we announced topline results from our Phase 2 LIGHTWAVE study in the treatment of mild cognitive impairment in Alzheimer’s disease. Read more: https://t.co/aY2Yohi6gm
We are incredibly honored to share that Sage Therapeutics, in collaboration with our partners at @biogen, has been named a winner for @PM360online's prestigious Trailblazer Award in the “Product Launch of the Year” category for our work in #PostpartumDepression.
Congratulations to all the finalists and winners, and a heartfelt thank you to @PM360online for an unforgettable evening. #PM360Trailblazers
Read more: https://t.co/KAU7kO3nBG
This weekend, the Sage team will be attending @EHDN_News & Enroll-HD 2024 in France. We look forward to sharing our #HuntingtonsDisease (HD) research, including an overview of our HD clinical studies. #EHDN2024
Update: We will present second quarter financial results on Wednesday, July 31st, 2024 at 4:30 pm ET via live webcast and conference call. Learn more: https://t.co/BG6uCCG79O $SAGE
We are proud to share that Matt Lasmanis, Sage's Chief Technology and Innovation Officer, has been named to @constellationr's #BT150 list! Learn more: https://t.co/8KqgexDe2L
We're looking forward to attending @GoldmanSachs 45th Annual Global Healthcare Conference on June 12th. Join us for a fireside chat at 2:00 pm ET here: https://t.co/clRilrQO2H